$AARD News

B. Riley Securities Maintains Buy on Aardvark Therapeutics, Lowers Price Target to $7

BTIG Downgrades Aardvark Therapeutics to Neutral

FDA Halts Aardvark Therapeutics Rare Disease Study

Morgan Stanley Downgrades Aardvark Therapeutics to Underweight, Lowers Price Target to $3

Aardvark Therapeutics Says FDA Places Full Clinical Hold On Its Investigational New Drug Application For ARD-101 Related To Prior Announced Voluntary Pause

Aardvark Therapeutics Q1 EPS $(0.99) Misses $(0.90) Estimate

BTIG Reiterates Buy on Aardvark Therapeutics, Maintains $9 Price Target

Aardvark Therapeutics Files Prospectus To Offer Up To $400M In Securities

Aardvark Therapeutics Announces Voluntary Pause Of The Phase 3 HERO And OLE Trials Evaluating ARD-101 For The Treatment Of Hyperphagia In Individuals With Prader-Willi Syndrome, Further Guidance On The Program Expected In Q2 2026

Aardvark Therapeutics Q4 EPS $(0.81) Beats $(0.91) Estimate

What's Going On With Aardvark Therapeutics Stock On Wednesday?

Monday's session: top gainers and losers

Let's uncover which stocks are experiencing notable gaps during today's session.

Aardvark Therapeutics shares are trading lower after multiple analyst firms lowered their respective price targets on the stock

Aardvark Therapeutics shares are trading lower after multiple analyst firms lowered their respective price targets on the stock

Get insights into the top gainers and losers of Monday's pre-market session.

Oppenheimer Maintains Outperform on Aardvark Therapeutics, Lowers Price Target to $21

This Novo Nordisk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

BTIG Maintains Buy on Aardvark Therapeutics, Lowers Price Target to $9

Market-Moving News for March 2nd